Floatz logo

Fam-Trastuzumab Deruxtecan-Nxki

HR Positive

QuantumLeap Healthcare CollaborativePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

116 Active assets in the HR Positive cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

Fam-Trastuzumab Deruxtecan-Nxki is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →